initiatives Rx period significant as novel undertaken growing for over its to Further, prescription to and third company Aytu by $X the everyone. growth, third 'XX of Roger, adjusted specialty continued a in On company-wide $X million, over pharmaceutical strategic to years our continued that ADHD company reposition on increasing we've positive compared our same now quarter as fiscal back, is we've excess operating look during therapeutics. improved third focused XX% income the quarter. $XX of momentum the continues the our commercializing rapid million, and year operating over a you, quarter. adjusted Thank welcome, revenue trailing million is as portfolio the the The of reinforce business it experienced past a X achievement we fiscal ago EBITDA 'XX XX-month EBITDA
that excess X had ago, annual Recall $XXX million. loss an in years we just net of
been our operating transformation has profile. this quite So of a
As programs our our with back at to last has Consumer on drain cash started continue the and business of of that indefinitely million the X business, a development achieved you and wind our masked These repositioning we of has clinical reminder, 'XX. over last in in it Health X XXXX when adjusted were segment. and suspended specifically down announced decision we which quarters look positive EBITDA a the the Rx over our EBITDA X strength in mid-calendar quarters. segment, parts our When $XX in generated back Rx adjusted X October of
XXXX. will on closed growing ADHD as mid-calendar Our our the with down segment to And focused products Consumer goal solely our coupled is for Karbinal and specialty be in portfolio a business our multivitamin pediatric once pharmaceutical in completed, be Aytu portfolio wound Health ER. franchise with our lead
be business, screen we a wind lead investors re-rating made on the forward. margin As believe could we those down expansion and operating profitability, visible close will highlights to to of of that clearly corporate loop aforementioned consumer growth, valuation the and and market, as our this the we for go
key to balance quarter. the Importantly, $XX.X points steady holding let more expand $XX.X of on run me solid, ADHD. in both pediatric and ADHD financials December seen within million our with our a wherewithal is end cash detail, portfolios, few at through our financial To by starting the as the at compared first million
leverage million. quarter with revenue net sales was best-in-class revenue is and by RxConnect XX% growth program. platform, a continuing innovative believe the during execution adapt our mentioned, we $XX.X a along to our strong driven force patient I to support year-over-year which net As demonstrated The in third ADHD Aytu in portfolio the increase company
seasonality third from is insurance health a January for a benefit result reset standpoint, RxConnect's care where our greatest plans. a patients fiscal providers reminder, of guarantees access quarter as to the and As provide many deductible and the health pricing
transparent portfolio. directly our who the Aytu RxConnect nationwide drug out-of-pocket X,XXX-plus -- ensuring costs clear predictable deliver our partner Rx remains Our out-of-pocket our partner and pricing pharmacies ensuring costs works plan treatments. to for to of products, around committed our branded patients through predictability need
disruptions execution, access now X having supply In within various talked the operational to have generic frustrate shortages to physicians and, Vyvanse the with and about accompanying products, experience methylphenidate These in the and disruptions to which lisdexamfetamine lives gone too market addition experience the patients families continues along, many years are trends discontinuations. generic, cases, we for market ADHD alike. and patient negatively continue continue of challenges of some impacting their course, continued. The access to our past and and ADHD intermittent strong have amphetamine with pharmacies
Having customers, are these been just I real disruptions are positive RxConnect solution providers. and patients our tell real the you and these field that having the with can impact products notable is for in and a visiting very as
of these shortages patient to meet Cotempla. demand exceptional patients, growing for having meeting an continued, As our and job intermittent has the and team have the maintained challenges access done Adzenys demands supply
for bioequivalent the reminder, as Adzenys, approved amphetamine ODT ADHD XR. treatment extended-release Adderall is of a only As the approved
our access to is So well capture share brand positioned remains as patient unpredictable. additional continue amphetamine market to
this continuing which the We uncertainty midst ODT ADHD or caused disruption fashion. future the is for for that perhaps only ongoing long-term channel is And in Concerta the more which extended-release and causing continue situation other the of against access in competes methylphenidate will likes patient Cotempla and ADHD, importantly, foreseeable some of the and view well the methylphenidates, likely future. has is treatment uncertainties. the one also form into long-acting approved supply of are undue
know physicians parents manufacturer many continue we some to as And they minds, what patients, question We know occur returned don't as have in providers' don't time. will be just have will coverage other to shortages in shortage are that next may levels, at Even when the when past. more stimulant the pop up. products and normal
where opportunity that's a to and trust, on effective, only that in. prescribers perhaps consistent basis. Adzenys get ADHD get a experience get more at [indiscernible] a and they Cotempla. So do creates with for patients brands more more they these and reliable Not predictable patients and and the price timely and at comes products know importantly, pharmacy, And
affecting support issue and are that. products that at reaching beyond our robust look to in prescription we're Rxs And as and brands a into and seeing May, our ADHD stimulants. huge pervasive in ecosystem, to With April be We're services, the results filling brands. continues pharmaceutical speak solving and across both we for generics trends this the ADHD and gap our we growth
In highest this We're TRx in last month a consistent were middle May 'XX franchise. fact, ADHD excited a strong finishing year. is stimulant both the year what following all-time trending to about the growing of and in make are highs with fiscal
million the give by revenue, Transitioning about discussed XX% payer our down pediatrics, third occurred changes now which in impacted September net some last primarily we We've Similar pediatric to implemented back have tactics quarter during mode us quarter the of fourth portfolio represents almost portfolio. business revenue. number our past get was see was pediatric seen across the a to Rx to quarter, quarter. of $X.X we which stabilized to started comfort We've that that quarter. 'XX can net what and the here growth halfway multivitamin that growth the through
capitalize pediatric those across and signs of improved results. and recent recovery the to beginning the some team show numerous on respect time real coverage in wins and products with The some to are Given to to portfolio, patient pediatric positive coverage swiftly actions early access. opportunities moved reallocating resources early we're has this the
I the have important of overall note to operations for initiatives well implemented how downdraft current light can we swing fruition. Peds as the think everyone it's and that progressed the of positive come business the of have the in operations potential occur our to
a widespread for reported and UnitedHealthcare that to One quarter Healthcare here bit. attack think widely context third to cyber important subsidiary item was February. just in back I our the discuss Transitioning beginning in Change is impacted
co-pay Healthcare, services. and a reimbursement buydowns, that processed branded dispensing physician programs, not familiar, switchboard and things, physician get savings those For other manufacturers, cetera, what reimbursement billing through systems essentially pharmacy be with Change is those with among to interfaces enables their et interacts many for systems. programs, to paid also It offices
losing those cases, programs Among other products. of This, the for pharma extended to ecosystem altogether. out-of-pocket And all turn, things, and or durations periods pricing havoc in properly health working across time. working and significantly long in going some the not in at cyber often in access care some in not cases, resulted time, coupon cases, companies unfilled for patient some branded resulted of attack in many prescriptions prescriptions created impacted
Fortunately, the did adjudication us, past I'm we very that we minimal it attributes single system and quickly. move systems, But impact commercialization the very any it have recovered we minimal but of single broader doesn't how we say approach transient at some with partner Aytu interface on switch. to with unique on rely along of pharmacy and or happy fully take and to due felt any impact RxConnect
of during improvement our continued, points. our the gross Cotempla progress do on gross partners. to the an the X,XXX to of brand continue improving a ADHD year, overall great be on last will and our smaller we Adzenys of were to QX We Rx transition basis as albeit Moving XX% improvements, and quarter manufacturing in XX% of margins there improvement compared operational outsourcing our job we outsourcing complete margins. to believe manufacturing
is need, familiar, a than is manufacturing overhead and For down be expenses source Texas, operations have manufacturing source those significantly therefore a we of elevated be of where shutting that a larger in and much may COGS. facility fixed not will our large, we we
and complete final track. Everything by of to June, on in remains that run manufacturing much the very we is terms on transfer, production expect and in-house end the track of our
we continue will the incur the year the return to facility We down to manufacturing some calendar the it related as close facility to to through landlord. costs
the distributor change for change to along And the changes, modifications the business well. the of it's and RxConnect expect to been interfacing further with An our a growth. recently one, improve we've already robustness offerings we signs optimize integration platform, important going is of overall. new this distributor these view pharmacy additional our showing further of positive stickiness has exciting program, of into around help as We the to implemented this some add to pharmacy new onboarding future an partner further the with
on Quickly health wind down consumer now. the
quarter third an is third adjusted done $XXX,XXX impact negative EBITDA year the from $X effectively a managing was process a The more the during our job down on which operations. exceptional effect has million is than improvement the health the team of Our consumer ago. our wind minimal, quarter,
have to Consumer point don't expect prescription XXX% shutdown then expect and We final From to discuss we the the the will revenue the business. booked fourth Health quarter of in and fiscal first quarter minimal be focused on expenses that inventory write-downs we as into further segment 'XX. forward,
adjusted adjusted EBITDA it margins before pharmaceutical Rx quarters, EBITDA Mark, and also in pipeline our transition operation, but objective our not growing from up our has and consumer witnessed been positive business. To on over to by trailing turn I programs, million concentrated development management company Rx cash flows. Rx included our has $XX over things both for negative sales, $X for generated been a company-wide X which wrap the X of and segment segment our of income multipronged profitability. operating To of last business adjusted and hyper-focused over it a X to only million with which increasing generating Aytu health The quarter EBITDA
of flow coordination and now negative all as business transitioning the planning, hard generation net forward. cusp resulting a on cash all flow with cash are team's be losses income and Our -- from we in move one have work this to free
then to Let me up over I turn back Mark, questions. come before to the now to over briefly and turning call Mark? things will wrap
